Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Short-term efficacy of oxaliplatin as interventional therapy for liver cancer, and its effect on serum CD163 and AFU

Sen Zhao¹, Liang Wang¹, Jiadong Xia¹, Lin Liu²

¹Department of Radiology, the Affiliated Hospital of Shaoxing University (Shaoxing Municipal Hospital), Shaoxing 312000, Zhejiang Province, China; ²Department of Operating Room, Shaoxing People's Hospital, Shaoxing 312000, Zhejiang Province, China.

For correspondence:- Lin Liu Email: rucaixian2300@163.com

Accepted: 28 January 2024 Published: 29 February 2024

Citation: Zhao S, Wang L, Xia J, Liu L. Short-term efficacy of oxaliplatin as interventional therapy for liver cancer, and its effect on serum CD163 and AFU. Trop J Pharm Res 2024; 23(2):409-414 doi: 10.4314/tjpr.v23i2.22

© 2024 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To investigate the short-term effectiveness of oxaliplatin in the interventional treatment of liver cancer, and its effect on serum CD163 and α-L-glucosidase (AFU).

Methods: Eighty liver carcinoma patients treated in The Affiliated Hospital of Shaoxing University, Shaoxing, China from January 2022 to January 2023 were allotted to 2 cohorts (each with 40 patients). Subjects in control group were treated with hepatic Transarterial Chemoembolization (TACE), while study group was treated with combination of hepatic TACE and oxaliplatin. Efficacy, serological indicators, health status and cancer-related fatigue were determined and compared between both cohorts.

Results: DCR was significantly higher in study group than in the control. There were significantly reduced post-treatment amounts of CYFRA21-1, CA125 and VGEF in the study cohort, relative to pre-treatment and control levels (p < 0.05). Post-treatment values of CD4+/CD8+ and CD4+ were significantly low, relative to levels before treatment, while CD8+ in both groups were significantly increased after treatment (p < 0.05). However, post-treatment T lymphocyte level was comparable in both groups. There was significantly higher post-treatment KPS score in study cohort than pre-treatment and control scores, but RPFS score was significantly reduced, relative to the corresponding pre-treatment and control scores. Post-treatment serum amounts of CD163 and AFU were significantly down-regulated in both cohorts, with lower levels in the study cohort.

Conclusion: The combined use of liver TACE and oxaliplatin produces good clinical outcome in the treatment of liver cancer. It is beneficial in reducing serum levels of CD163 and AFU, inhibits proliferation of tumor cells, reduces tumor volume, and improves cancer prognosis in patients.

Keywords: Oxaliplatin, Liver cancer, Interventional therapy, Short-term efficacy, ?- L-glucosidase